Neuroendocrine neoplasms (NENs) represent rare and heterogeneous malignancies, predominantly manifesting within the gastrointestinal tract and lungs. At initial diagnosis, between 12 to 22 percent of cases present with metastases [1, 2].

The diverse nature of NENs poses a challenge in determining optimal therapeutic strategies, often necessitating a multidisciplinary approach for tailored decision-making. One such therapeutic approach for managing liver metastases involves Transarterial Chemoembolization (TACE) [3, 4]. However, discerning its suitability remains a complex task.

Radiomics emerges as a potential solution, offering support in therapy selection and decision-making processes. Notably, in NENs, radiomics has been employed to predict therapy response, particularly in treatment with everolimus [5]. While other studies have explored its utility in predicting therapy response in hepatocellular carcinoma patients undergoing TACE [6], its application in predicting therapy response after TACE for NEN patients remains uncharted territory.